Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
复制标题
晚期非小细胞肺癌中循环肿瘤DNA引导的疗法的总生存期。
DOI:
10.1038/s41591-022-02047-z
复制
发表时间:
2022-11
期刊:
影响因子:
82.9
通讯作者:
Li, Bob T.
中科院分区:
文献类型:
--
作者:
Jee, Justin;Lebow, Emily S.;Yeh, Randy;Das, Jeeban P.;Namakydoust, Azadeh;Paik, Paul K.;Chaft, Jamie E.;Jayakumaran, Gowtham;Brannon, A. Rose;Benayed, Ryma;Zehir, Ahmet;Donoghue, Mark;Schultz, Nikolaus;Chakravarty, Debyani;Kundra, Ritika;Madupuri, Ramyasree;Murciano-Goroff, Yonina R.;Tu, Hai-Yan;Xu, Chong-Rui;Martinez, Andres;Wilhelm, Clare;Galle, Jesse;Daly, Bobby;Yu, Helena A.;Offin, Michael;Hellmann, Matthew D.;Lito, Piro;Arbour, Kathryn C.;Zauderer, Marjorie G.;Kris, Mark G.;Ng, Kenneth K.;Eng, Juliana;Preeshagul, Isabel;Lai, W. Victoria;Fiore, John J.;Iqbal, Afsheen;Molena, Daniela;Rocco, Gaetano;Park, Bernard J.;Lim, Lee P.;Li, Mark;Tong-Li, Candace;De Silva, Madhawa;Chan, David L.;Diakos, Connie, I;Itchins, Malinda;Clarke, Stephen;Pavlakis, Nick;Lee, Adrian;Rekhtman, Natasha;Chang, Jason;Travis, William D.;Riely, Gregory J.;Solit, David B.;Gonen, Mithat;Rusch, Valerie W.;Rimner, Andreas;Gomez, Daniel;Drilon, Alexander;Scher, Howard, I;Shah, Sohrab P.;Berger, Michael F.;Arcila, Maria E.;Ladanyi, Marc;Levine, Ross L.;Shen, Ronglai;Razavi, Pedram;Reis-Filho, Jorge S.;Jones, David R.;Rudin, Charles M.;Isbell, James M.;Li, Bob T.
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an international cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy. ctDNA detection was associated with shorter survival (hazard ratio (HR), 2.05; 95% confidence interval (CI), 1.74–2.42; P < 0.001) independently of clinicopathologic features and metabolic tumor volume. Among the 722 (64%) patients with detectable ctDNA, 255 (23%) matched to targeted therapy by ctDNA sequencing had longer survival than those not treated with targeted therapy (HR, 0.63; 95% CI, 0.52–0.76; P < 0.001). Genomic alterations in ctDNA not detected by time-matched tissue sequencing were found in 25% of the patients. These ctDNA-only alterations disproportionately featured subclonal drivers of resistance, including RICTOR and PIK3CA alterations, and were associated with short survival. Minimally invasive ctDNA profiling can identify heterogeneous drivers not captured in tissue sequencing and expand community access to life-prolonging therapy.
登录
查看更多内容
影响因子:
16.6
作者:
Chabon JJ;Simmons AD;Lovejoy AF;Esfahani MS;Newman AM;Haringsma HJ;Kurtz DM;Stehr H;Scherer F;Karlovich CA;Harding TC;Durkin KA;Otterson GA;Purcell WT;Camidge DR;Goldman JW;Sequist LV;Piotrowska Z;Wakelee HA;Neal JW;Alizadeh AA;Diehn M
通讯作者:
Diehn M
DOI:
10.1016/j.jtho.2018.03.035
发表时间:
2018-08
期刊:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子:
--
作者:
Lisberg A;Cummings A;Goldman JW;Bornazyan K;Reese N;Wang T;Coluzzi P;Ledezma B;Mendenhall M;Hunt J;Wolf B;Jones B;Madrigal J;Horton J;Spiegel M;Carroll J;Gukasyan J;Williams T;Sauer L;Wells C;Hardy A;Linares P;Lim C;Ma L;Adame C;Garon EB
通讯作者:
Garon EB
影响因子:
64.8
作者:
Karczewski, Konrad J;Francioli, Laurent C;MacArthur, Daniel G
通讯作者:
MacArthur, Daniel G
影响因子:
28.4
作者:
Aggarwal, Charu;Thompson, Jeffrey C.;Carpenter, Erica L.
通讯作者:
Carpenter, Erica L.
影响因子:
120.7
作者:
Kris, Mark G.;Johnson, Bruce E.;Berry, Lynne D.;Kwiatkowski, David J.;Iafrate, A. John;Wistuba, Ignacio I.;Varella-Garcia, Marileila;Franklin, Wilbur A.;Aronson, Samuel L.;Su, Pei-Fang;Shyr, Yu;Camidge, D. Ross;Sequist, Lecia V.;Glisson, Bonnie S.;Khuri, Fadlo R.;Garon, Edward B.;Pao, William;Rudin, Charles;Schiller, Joan;Haura, Eric B.;Socinski, Mark;Shirai, Keisuke;Chen, Heidi;Giaccone, Giuseppe;Ladanyi, Marc;Kugler, Kelly;Minna, John D.;Bunn, Paul A.
通讯作者:
Bunn, Paul A.